Bessemer Group Inc. Has $331,000 Holdings in Biogen Inc. (BIIB)
Bessemer Group Inc. lowered its position in Biogen Inc. (NASDAQ:BIIB) by 24.3% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,058 shares of the biotechnology company’s stock after selling 340 shares during the quarter. Bessemer Group Inc.’s holdings in Biogen were worth $331,000 as of its most recent filing with the Securities and Exchange Commission.
Several other large investors have also recently made changes to their positions in BIIB. Pathstone Family Office LLC bought a new position in shares of Biogen in the first quarter valued at approximately $102,000. Prentiss Smith & Co. Inc. boosted its holdings in Biogen by 14.9% during the second quarter. Prentiss Smith & Co. Inc. now owns 385 shares of the biotechnology company’s stock worth $104,000 after buying an additional 50 shares in the last quarter. Atlantic Trust LLC bought a new stake in Biogen during the second quarter worth approximately $114,000. Independent Portfolio Consultants Inc. boosted its holdings in Biogen by 93.2% during the second quarter. Independent Portfolio Consultants Inc. now owns 454 shares of the biotechnology company’s stock worth $123,000 after buying an additional 219 shares in the last quarter. Finally, Carroll Financial Associates Inc. boosted its holdings in Biogen by 1.2% during the second quarter. Carroll Financial Associates Inc. now owns 496 shares of the biotechnology company’s stock worth $134,000 after buying an additional 6 shares in the last quarter. Institutional investors own 88.35% of the company’s stock.
Shares of Biogen Inc. (NASDAQ:BIIB) opened at $313.97 on Friday. The company has a current ratio of 2.19, a quick ratio of 1.90 and a debt-to-equity ratio of 0.46. Biogen Inc. has a 1 year low of $244.28 and a 1 year high of $348.84. The stock has a market cap of $66,397.44, a price-to-earnings ratio of 14.54, a price-to-earnings-growth ratio of 1.96 and a beta of 0.72.
Biogen (NASDAQ:BIIB) last issued its quarterly earnings data on Tuesday, October 24th. The biotechnology company reported $6.31 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $5.70 by $0.61. Biogen had a net margin of 29.44% and a return on equity of 38.51%. The company had revenue of $3.08 billion for the quarter, compared to analyst estimates of $3.05 billion. During the same period in the prior year, the firm earned $5.19 earnings per share. The company’s revenue was up 4.1% on a year-over-year basis. equities analysts anticipate that Biogen Inc. will post 22.03 EPS for the current fiscal year.
A number of equities analysts recently commented on the stock. Citigroup Inc. lowered shares of Biogen from a “buy” rating to a “neutral” rating in a research note on Monday, October 23rd. Vetr lowered shares of Biogen from a “strong-buy” rating to a “buy” rating and set a $319.53 price objective for the company. in a research note on Wednesday, August 23rd. Stifel Nicolaus reaffirmed a “hold” rating and issued a $300.00 price objective on shares of Biogen in a research note on Thursday, October 12th. Mizuho set a $400.00 price objective on shares of Biogen and gave the stock a “buy” rating in a research note on Monday, November 13th. Finally, Robert W. Baird reaffirmed a “hold” rating and issued a $290.00 price objective on shares of Biogen in a research note on Friday, August 25th. Twelve investment analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $341.89.
WARNING: This piece of content was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece of content on another domain, it was stolen and reposted in violation of United States and international copyright laws. The original version of this piece of content can be read at https://www.thecerbatgem.com/2017/11/19/bessemer-group-inc-has-331000-holdings-in-biogen-inc-biib.html.
Biogen Inc is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA).
Receive News & Stock Ratings for Biogen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen Inc. and related stocks with our FREE daily email newsletter.